<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492858/" ref="ordinalpos=829&amp;ncbi_uid=5433558&amp;link_uid=PMC3492858" image-link="/pmc/articles/PMC3492858/figure/F8/" class="imagepopup">Fig. 8. From: The Wnt <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. </a></div><br /><div class="p4l_captionBody">A schematic presentation of the role of Wnt signaling and TCF7L2 in hepatic gluconeogenesis. Feeding upregulates plasma insulin levels, which leads to β-cat Ser675 phosphorylation and TCF7L2 expression. A: increased levels of TCF7L2 may repress gluconeogenesis via competing with forkhead box O (FoxO) for β-cat. B: in addition, cat/TCF7L2, as the effector of the Wnt signaling pathway, may possess an intrinsic repressive effect on gluconeogenesis. P, Ser675 phosphorylation.</div></div>